Sixth-generation test transforms emergency heart attack diagnosis

Roche has announced results from the TSIX Study Program, showing that its sixth-generation high-sensitivity Troponin T test delivers unprecedented accuracy in diagnosing heart attacks. Recently granted CE Mark, the Elecsys® Troponin T hs Gen 6 test allows clinicians to quickly identify acute myocardial infarction (AMI) while ruling out non-cardiac causes, ensuring patients receive timely care.

The TSIX program involved over 13,000 participants across the US, China, Japan, and Europe, validating the test in real-world clinical settings. Study results presented at the European Society for Emergency Medicine and the European Society of Cardiology conferences demonstrated that the test accurately detects AMI and identifies patients who do not have a heart attack, supporting rapid and efficient triage in emergency departments.

Chest pain is one of the most common reasons for emergency visits, yet only a small proportion of patients are experiencing a heart attack. With emergency departments often facing overcrowding, the ability to quickly and reliably identify those in need of urgent care is critical for patient outcomes and effective use of resources.

“Coronary artery disease continues to place immense strain on healthcare systems, particularly in emergency care,” said Matt Sause, CEO of Roche Diagnostics. “Our new test detects even minimal elevations in troponin levels, a key biomarker of heart attack, giving clinicians the confidence to act quickly. Every second counts, and this test ensures patients receive life-saving care without delay, while resources can be prioritised effectively.”

Roche has a 30-year legacy in troponin innovation, having introduced the first high-sensitivity troponin tests and the first FDA-approved assay. The sixth-generation test represents the next step in managing coronary artery disease, combining precise biomarker measurement with a growing portfolio of assays and digital solutions that support both laboratory and near-patient diagnostics.

The TSIX Study Program confirms that the Elecsys® Troponin T hs Gen 6 test delivers fast, reliable, and accurate results, enabling emergency clinicians to make informed decisions and improving outcomes for patients with suspected heart attacks.

More information online